Financial News
Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors
![](https://www.thenewswire.com/data/tnw/clients/logos/Av7FEx6M.png)
![](https://www.thenewswire.com/data/tnw/img/facebook.png)
![](https://www.thenewswire.com/data/tnw/img/twitter.png)
![](https://www.thenewswire.com/data/tnw/img/linkedIn.png)
![](https://www.thenewswire.com/data/tnw/img/youTube.png)
LONDON, ONTARIO – TheNewswire - May 4, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that seasoned pharmaceutical industry executive, Dr. Mohammad Azab, MB ChB, MSc, MBA, has been nominated by the Company to its Board of Directors.
“Dr. Azab’s extensive knowledge and experience in the pharmaceutical industry, as well as his many industry connections, make him an excellent fit for the Board of Sernova, particularly as the Company expands its clinical development programs for the treatment of chronic diseases such as diabetes, thyroid and rare diseases,” said Frank Holler, Chairman of the Board of Sernova. “Dr. Azab’s appointment further supports the Company’s near-term goal to bolster its Board of Directors, as well as Scientific Advisory and Global Advisory Boards, in line with our expanding research, development and business activities.”
Dr. Azab served as President and Chief Medical Officer of Astex Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery and development of drugs in oncology and other disease indications. As of November 2020, upon retirement from his management role, Dr. Azab has served as the Chair of the Board of Directors for Astex Pharmaceuticals, Inc, which is now a wholly-owned subsidiary of Otsuka Pharmaceuticals. Previously, Dr. Azab served as President and CEO of Intradigm Corporation, a developer of siRNA cancer therapeutics. Prior to this, Dr. Azab served as Executive Vice President of Research and Development and Chief Medical Officer of QLT Inc., and in several leadership positions at AstraZeneca in the United Kingdom and Sanofi Pharmaceuticals in France. Dr. Azab holds his medical degree (MB ChB) from Cairo University and an MBA from the Richard Ivey School of Business, Western University, Ontario. He received post-graduate training and degrees in oncology research from the University of Paris-Sud and biostatistics from the University of Pierre et Marie Curie in Paris, France.
“I am excited to be nominated to join Sernova’s Board of Directors,” said Dr. Mohammad Azab. “I intend to bring my experience and additional perspectives to support Sernova and its management team as the company progresses it novel regenerative medicine therapeutic programs with the aim to provide a ‘functional cure’ for patients suffering from chronic diseases.”
Dr. Azab has more than 30 years of experience in clinical research, business management and led the global development of several drugs currently approved in oncology and other therapeutic areas. Currently, he also serves on the board of directors of NASDAQ listed companies, Xenon Pharmaceuticals Inc. (XENE), and Durect Corporation (DRRX).
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device, therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and immune protection technologies to improve the treatment and quality of life of people living with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.